# CharlestonPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/charlestonpharma

- Industry: Healthcare
- Headquarters: Charleston, US
- Website: www.charlestonpharma.com
- Total disclosed funding: $1.6M
- Latest round: Seed (Jan 29, 2013)
- Investors on record: 2

## About

CharlestonPharma, LLC is a biopharmaceutical company focused on developing innovative therapeutic solutions for cancer treatment, particularly through its lead product, the IgG1 monoclonal antibody CP101.2C8.CharlestonPharma is engaged in the development of cancer therapies, specifically through its lead product, CP101.2C8. Founded by Robert Capizzi and headquartered in Charleston, US, the company raised USD 1.6 mn in Seed funding on January 29, 2013, from investors including Sears Capital Management and Upstate Carolina Angel Network.CharlestonPharma specializes in developing innovative therapeutic solutions centered around its lead product, the IgG1 monoclonal antibody CP101.2C8. This antibody targets the nucleolin transporter on tumor cells, destabilizing oncogenic mRNAs, which leads to apoptosis in various cancer cell lines. CP101.2C8 is aimed at healthcare providers, oncologists, and research institutions involved in cancer treatment, marketed in North America and select European markets.CharlestonPharma's revenue generation model is based on partnerships with healthcare providers and research institutions for clinical trials and commercialization of CP101.2C8. The company may enter into collaborative agreements with pharmaceutical firms, involving upfront and milestone payments related to clinical trial progress, along with potential royalties on future sales. Revenue streams are expected to comprise both licensing fees and product sales generated through B2B relationships with hospitals and oncology treatment centers.CharlestonPharma plans to leverage the recent USD 1.6 mn Seed funding raised on January 29, 2013, to enhance its product development and market presence. The company is focusing on advancing CP101.2C8 and exploring new partnerships within North America and Europe. Strategic initiatives include expanding into additional oncology markets and developing new therapeutic solutions to address unmet medical needs in cancer treatment.

## Funding rounds

- Seed, Jan 29, 2013, $1.6M — Sears Capital Management, Upstate Carolina Angel Network

## Investors

- Sears Capital Management (https://capitalatlas.ai/funds/sears-capital-management) — Seed
- Upstate Carolina Angel Network — Seed